Company Overview
Lifecore Biomedical, Inc. operates as an integrated contract development and manufacturing organization serving a global client base that includes locations in the United States, Belgium, the Netherlands, and other international markets. The company is situated within the Healthcare sector and specifically functions in the Drug Manufacturers - Specialty & Generic industry, providing specialized services in the development, manufacture, aseptic fill, and related pharmaceutical processes. The organization maintains a workforce of 400 employees and holds a total market capitalization of $137.17M. With annual revenue reaching $129.46M, these financial figures indicate that the company holds a mid-cap position in its niche, suggesting it is a specialized player rather than a dominant market leader, yet one with sufficient scale to support complex manufacturing operations.
Financial Health
The company reported total revenue of $129.46M over the trailing twelve months, while generating a net income of $-34,503,432 and an EBITDA of $8.24M. The significant gap between the positive revenue of $129.46M and the substantial net loss of $-34,503,432 reveals a cost structure where operating expenses, likely including research, development, and administrative costs, heavily outweigh the profits derived from gross sales. Regarding liquidity, the free cash flow metric is listed as N/A, which implies that the company may be relying on financing or operating cash flows rather than generating surplus cash for reinvestment or debt repayment in the current reporting period. The gross margin stands at 31.4%, indicating that the company retains roughly one-third of its revenue after direct production costs, while the operating margin of 8.2% suggests that overhead and operational expenses consume a majority of the remaining revenue. The profit margin is negative at -23.8%, reflecting that the total operating expenses exceed total revenue before interest and taxes, resulting in an overall loss on sales. The company holds $17.47M in cash against total debt of $141.28M, resulting in a debt-to-equity ratio of 414.80, which characterizes the balance sheet as highly leveraged rather than conservative. Despite the high leverage, the current ratio of 3.49 indicates strong short-term liquidity, as the company possesses more than three times the current assets required to cover its current liabilities. Return on Equity and Return on Assets are both N/A, which precludes a direct assessment of management effectiveness in generating returns on shareholder equity or total assets at this specific point in time.
Valuation Assessment
The valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to the reported net losses, while the forward P/E is listed as -4.41. The disparity between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in a significant turnaround in earnings trajectory or that current earnings are not a reliable basis for valuation. The price-to-book ratio is -9.66, which indicates that the market values the company at a significant discount to its book value, a common characteristic for firms with intangible assets or those currently unprofitable. Alternative valuation metrics such as the price-to-sales ratio of 1.06 and the EV/EBITDA of 37.52 suggest that the market is valuing the company primarily on its sales revenue and enterprise value relative to earnings before interest, taxes, depreciation, and amortization, rather than current profitability. The stock has traded within a range defined by a 52-week high of $8.98 and a 52-week low of $3.64, placing the current trading environment within this volatility band. The beta value of 0.64 indicates that the stock exhibits lower price volatility relative to the broader market, moving less than half as much as the market index on average during periods of fluctuation.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning that specific growth rates cannot be calculated from the current data points provided. In the absence of positive earnings growth rates, the company does not currently generate excess profits to distribute, resulting in a dividend yield of N/A and a payout ratio of 0.0%. Since the company is not a dividend payer, it effectively reinvests any operational cash flows or potential future earnings back into its contract development and manufacturing operations rather than paying dividends to shareholders. The overall growth and income profile is currently defined by a lack of historical growth data and a zero-dividend strategy, reflecting a company in a phase of operational scaling or financial restructuring where capital retention is prioritized over shareholder income distribution.